Apax Partners' Unilabs to buy Biopath, Polibio, SFMTBio

News portal Capital Finance reported that the transactions were organised by Natixis Partners.

Apax declined to comment on the transaction, while Natixis was not available for comment.

The three businesses combined generated a turnover of around €100m, 80% of which is from the biggest of the three businesses,  Biopath. It posts an EBITDA of €20m, according to the news channel Capital Finance.

Apax acquired Switzerland-based medical diagnostics provider Unilabs from Nordic Capital and Apax Partners France in 2016. Apax Partners invested via its Apax IX vehicle. The capital injection was intended to allow the company to boost its M&A strategy and further consolidate the European laboratory space.

Founded in 1987, Unilabs is a clinical laboratory testing and medical diagnostics provider based in Geneva. The company manages 230 laboratories and 92 medical imaging units, based in Europe, South America and Asia. The company has 10,500 employees and generates sales around €900m according to its website.

The three laboratory branches operate in France exclusively, with Biopath running 30 laboratories, SFMTBio seven and Polibio three.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• France
• Healthcare
• France
• Apax Partners